Rezultati pretraživanja
  1. prije 8 sati
  2. 4. velj
  3. 1. velj

    An urgent reminder of what is at stake, as misguided policies on threaten to disable world-leading US .

  4. Why do companies pay the highest rents in New England to be in Cambridge’s Kendall Square?

  5. 31. sij

    Gr8 to see from our industry being applied to a major global public health emergency. So important to remember this when some demonize our industry! Thank you !!

  6. 30. sij
  7. 30. sij

    Tethered to tissue-based cancer detection while rivals focus on blood-based tests, Adaptive's sharp valuation is heading towards a correction 🩸

  8. 30. sij

    Interesting discussion with our CEO in on targeting the to potentially combat malignant diseases, including .

  9. 29. sij

    The suburbs are cheaper, but they don’t have what Kendall Square has for : 'serendipity' via and

  10. 12. sij

    Welcome EQRx! It’s gr8 to have new Cos aimed at lower drug prices thru market-based competition. As we know from generics, that’s an approach that works!

  11. 10. sij

    In and today, the “old” culture of discovery — the idea that is driven by discovering new knowledge (hypothesis —> test —> repeat) — is clashing with the “new” culture of (design —> test —> iterate).

  12. 8. sij

    Proud to join >200 leaders committed to patients and innovation in making this statement. It’s time to take our industry back!

  13. 16. pro 2019.

    The entire process relies on investors, academics, govt, & . Policies, like those proposed in Congress today, that threaten one of these actors will ultimately bring down the entire ecosystem. More from

  14. 4. pro 2019.

    Cool graphic from showing the complement pathway overlaid with relevant deals and drug approvals Dec 2019 Issue:

    Prikaži ovu nit
  15. 30. lis 2019.

    simultaneously enables both granular ownership, sovereignty, and , as well as accessibility of data across a highly complex set of stakeholders: patients, health systems, insurers, gov agencies, ...

  16. “They have intentionally created an IP system that is biased in favor of Chinese generic firms.” The regime is seeking dominance in by using a range of "unfair means," threatening global drug innovation, accord to a report.

  17. 21. kol 2019.

    Interview with Sven Borho from flags a tougher stance from the FDA on companies, as evidenced by recent events with & . Other Topics: , Chinese , M&A Likely M&A Targets:

  18. 12. tra 2019.

    Pleased to have run my letter to the editor today. It’s critically important that speak up to ensure that the drug pricing discourse isn’t dominated by misinformation.

  19. 2. tra 2019.

    Full service,therapeutic antibody discovery co, (TSXV:IPA)(Pink:IPATF),expands service offerings in response to large-scale delivery pgm w/ US-based pharma co.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.